{"entity":{"id":"predomix","kind":"company","name":"PredOmix","aka":["PredOmix Technologies","PredOmix Health Sciences"],"tldr":"An Indian company with a Singapore affiliate that develops OncoVeryx, a serum metabolomics blood test it reports can detect 30 cancers.","summary":"PredOmix Technologies Private Limited, Gurugram, and PredOmix Health Sciences, Singapore, according to their authors' affiliations, combine untargeted serum metabolomics with machine learning. Its employees have published versions of the test for four, fifteen and thirty cancers, the last in an investigator-initiated trial with HCG cancer centres (CTRI/2023/03/050316).","asOf":"2026-11-03","links":[{"label":"Nagarkar et al., Cancer Reports 2024","url":"https://doi.org/10.1002/cnr2.70042"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection","diagnostics"],"technologies":["mced","liquid-biopsy"],"targets":[],"drugs":["oncoveryx"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Gurugram","country":"IN","companyType":"diagnostics","investors":[],"funding":[]},"route":"/companies/predomix/","neighbours":{"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"drug":[{"id":"oncoveryx","kind":"drug","name":"OncoVeryx (PredOmix)","route":"/drugs/oncoveryx/"}],"paper":[{"id":"paper-predomix-metabolome-cancer-rep-2024","kind":"paper","name":"Development of a Serum Metabolome-Based Test for Early-Stage Detection of Multiple Cancers","route":"/key-papers/paper-predomix-metabolome-cancer-rep-2024/"}]}}